Do you want to read an article? Please log in or register.
Opioid Use and Outcomes in Patients Hospitalized With Acute Severe Ulcerative Colitis
Inflammatory Bowel Disease
Related content
COMMENTED
Inflammatory Bowel Disease
Long-Term Outcome of Ciclosporin and Infliximab as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Inflamm Intest Dis
Grob F, Häberling I, Novacek G, Kreienbühl A, Biedermann L, Rogler G, Schreiner P
doi: 10.1159/000546511
Inflammatory Bowel Disease
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis
Clin Gastroenterol Hepatol
Honap S, St-Pierre J, Colwill M, Patel K, Le Berre C, Caron B, Nogami A, Kobayashi T, Altwegg R, Laharie D, Hebuterne X, Nachury M, Roblin X, Uzzan M, Kotze PG, Lukáš M, Vieujean S, D'Amico F, Albshesh A, Guillo L, Fumery M, Nancey S, Ye BD, Bergemalm D, Halfvarson J, Buisson A, Karmiris K, Rubin D, Vicaut E, Peyrin-Biroulet L, ATTRACT Study Group
doi: 10.1016/j.cgh.2025.07.025
Inflammatory Bowel Disease
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
J Crohns Colitis
Colombel JF, Wu J, Kobayashi T, Zhu B, Paulissen J, Dhanabal A, Jairath V, Siegel C, Siegmund B, Redondo I, Moses R, Magro F
doi: 10.1093/ecco-jcc/jjaf124
Gastrointestinal Cancer
The Impact of Advanced Medical Therapies on Time to Resection and Colorectal Cancer Outcomes in Ulcerative Colitis Patients Undergoing Colectomy
J Crohns Colitis
Visser E, Luberto A, Heuthorst L, Hompes R, Vermeire S, D'Haens GR, Bemelman WA, D'Hoore A, Bislenghi G, Buskens CJ
doi: 10.1093/ecco-jcc/jjaf015
Inflammatory Bowel Disease
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Lancet Gastroenterol Hepatol
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P
doi: 10.1016/S2468-1253(24)00200-0
Inflammatory Bowel Disease
Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN
Inflamm Bowel Dis
Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, Wlazlo M, Olbjørn C, Rungoe C, Weil N, Turner D, Cohen S
doi: 10.1093/ibd/izaf166
Inflammatory Bowel Disease
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study
Lancet Gastroenterol Hepatol
Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S
doi: 10.1016/S2468-1253(25)00017-2
Inflammatory Bowel Disease
Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study
Am J Gastroenterol
Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V
doi: 10.14309/ajg.0000000000003212
Inflammatory Bowel Disease
Efficacy and Safety of Etrasimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Baseline Modified Mayo Score: A Post Hoc Analysis From the Phase 3 ELEVATE UC Clinical Program
Inflamm Bowel Dis
Sands BE, Dubinsky MC, Kotze PG, Vermeire S, Panaccione R, Long MD, Woolcott JC, Wu J, McDonnell A, Goetsch M, Bananis E, Yarur AJ
doi: 10.1093/ibd/izaf036